Stay updated on Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The RELATIVITY-047 record now displays details of the study comparing relatlimab plus nivolumab with nivolumab alone for advanced melanoma, including its design, eligibility criteria, results measures, and locations. It also provides study documents and related publications.
    Difference
    100%
    Check dated 2026-11-11T17:30:32.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-10-28T15:44:48.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    A banner announces NIH’s terminology transition, saying federal agencies are using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI) and linking to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-21T21:59:44.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2 on the 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-10-14T22:02:35.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The footer now identifies the site revision as v3.7.1 instead of v3.7.0.
    Difference
    0.2%
    Check dated 2026-10-07T22:15:36.000Z thumbnail image
  7. Check
    54 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the previous study content. This blocks access to the RELATIVITY-047 study details and related information.
    Difference
    18%
    Check dated 2026-09-23T21:53:46.000Z thumbnail image

Stay in the know with updates to Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial page.